Insider Selling: BioLife Solutions, Inc. (NASDAQ:BLFS) EVP Sells $352,960.20 in Stock

BioLife Solutions, Inc. (NASDAQ:BLFS) EVP Aby J. Mathew sold 17,604 shares of the business’s stock in a transaction dated Monday, November 18th. The shares were sold at an average price of $20.05, for a total value of $352,960.20. Following the sale, the executive vice president now owns 284,442 shares in the company, valued at approximately $5,703,062.10. The trade was a 5.83 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

BioLife Solutions Stock Performance

Shares of BLFS stock opened at $25.39 on Friday. The company has a market capitalization of $1.18 billion, a P/E ratio of -23.95 and a beta of 1.88. The business’s 50 day moving average is $23.96 and its two-hundred day moving average is $22.88. The company has a current ratio of 2.78, a quick ratio of 1.78 and a debt-to-equity ratio of 0.03. BioLife Solutions, Inc. has a 12-month low of $11.91 and a 12-month high of $28.88.

Hedge Funds Weigh In On BioLife Solutions

A number of hedge funds have recently bought and sold shares of the business. Stifel Financial Corp boosted its position in BioLife Solutions by 5.4% during the third quarter. Stifel Financial Corp now owns 12,988 shares of the medical equipment provider’s stock worth $325,000 after purchasing an additional 670 shares in the last quarter. Louisiana State Employees Retirement System raised its holdings in shares of BioLife Solutions by 4.0% during the second quarter. Louisiana State Employees Retirement System now owns 18,300 shares of the medical equipment provider’s stock valued at $392,000 after acquiring an additional 700 shares during the last quarter. GAMMA Investing LLC raised its holdings in shares of BioLife Solutions by 29.4% during the third quarter. GAMMA Investing LLC now owns 3,295 shares of the medical equipment provider’s stock valued at $83,000 after acquiring an additional 748 shares during the last quarter. The Manufacturers Life Insurance Company increased its holdings in shares of BioLife Solutions by 5.8% in the second quarter. The Manufacturers Life Insurance Company now owns 13,825 shares of the medical equipment provider’s stock valued at $296,000 after purchasing an additional 753 shares during the last quarter. Finally, Sei Investments Co. increased its holdings in shares of BioLife Solutions by 1.4% in the first quarter. Sei Investments Co. now owns 60,191 shares of the medical equipment provider’s stock valued at $1,117,000 after purchasing an additional 839 shares during the last quarter. Hedge funds and other institutional investors own 93.24% of the company’s stock.

Analyst Ratings Changes

BLFS has been the topic of a number of recent research reports. HC Wainwright lowered their target price on BioLife Solutions from $29.00 to $27.00 and set a “buy” rating on the stock in a research note on Monday. Northland Securities upped their target price on BioLife Solutions from $26.00 to $28.00 and gave the stock an “outperform” rating in a research note on Friday, August 9th. Craig Hallum upped their target price on BioLife Solutions from $30.00 to $32.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. Finally, TD Cowen upped their target price on BioLife Solutions from $28.00 to $31.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. One investment analyst has rated the stock with a sell rating and six have issued a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $27.50.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.